Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions

Ítems similars

• Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
  per: Patoulias, Dimitrios, et al.
  Publicat: (2019)
• Sodium–glucose co‐transporter‐2 inhibitors and arterial stiffness: Class effect or drug effect?
  per: Patoulias, Dimitrios, et al.
  Publicat: (2020)
• A Response To: Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
  per: Bossi, Antonio C., et al.
  Publicat: (2020)
• Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
  per: Patoulias, Dimitrios, et al.
  Publicat: (2021)
• Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
  per: Patoulias, Dimitrios, et al.
  Publicat: (2020)